Skip to content

Evaluation of Plenum® Tissue Ortho to Prevent Epidural Fibrosis and Post-laminectomy Syndrome.

Evaluation of the Performance and Safety of Plenum® Tissue Ortho for the Prevention of Epidural Fibrosis and Post-laminectomy Syndrome After Microdiscectomy, for the Treatment of Disc Herniation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05776628
Enrollment
36
Registered
2023-03-20
Start date
2024-04-30
Completion date
2025-04-30
Last updated
2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herniated Disk Lumbar

Brief summary

The goal of this clinical trial is to compare if adding a polydioxanone membrane prevents epidural fibrosis and, consequently, the rate of occurrence of the post-laminectomy syndrome in participants undergoing microdiscectomy for treatment of disc herniation.

Detailed description

Participants will be submitted to microdiscectomy with the addition of a polydioxanone membrane over the dura mater in the test group and without in the control group. The groups will be compared regarding improving patients' quality of life, evaluation of epidural fibrosis, and device safety.

Interventions

DEVICEPlenum® Tissue ortho membrane (polydioxanone membrane)

Membrane addition after flavectomy and spinal nerve and dura mater manipulation.

Sponsors

Irmandade da Santa Casa de Misericordia de Sao Paulo
CollaboratorOTHER
M3 Health
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Pain radiating to one of the legs confirmed with an MRI scan; * Patients who have already undergone conservative treatment (treatment with medication and physiotherapy) for at least 6 weeks, but have not shown improvement; * Non-pregnant women or women of childbearing age who use contraceptive methods; * Having signed the free and informed consent form (TCLE).

Exclusion criteria

* Patients with concomitant pathologies (eg infection or tumor and segmental instability or vertebral fractures); * Cauda equina syndrome; * Strength deficit characterized by strength equal to or less than III/V; * Previous surgery of the lumbar spine; * Patientes who have wound healing disorders; * Patients with contraindications for evaluating MRI with the use of contrast; * More than 1 herniated disk.

Design outcomes

Primary

MeasureTime frameDescription
Patient's quality of lifeChange from the baseline, to immediate potostoperative period (14 days) and to late postoperative period (6 months).Assessed by the Oswestry Questionnaire for lumbar evaluation (The low back pain disability Oswestry questionnaire).

Secondary

MeasureTime frameDescription
Epidural fibrosis6 months postoperatively.Evaluation of epidural fibrosis using Magnetic Resonance Imaging (IMR) will grade the scar from 0 to 4 for 5 contiguous axial slices centered around the intervertebral disc. The scar will be graded as none (0) (no scar on the dural surface), mild (1) (scar on less than 25% of the surface), mild-moderate (2) (scar on 25-50 % of the surface), (3) moderate-extensive (scarring on 50-75% of the surface), or extensive (4) (scarring on more than 75% of the surface).
Patient's quality of lifeBefore the procedure, in the immediate postoperative period (14 days) and in the late postoperative period (6 months).SF-36 Questionnaire
Low back and leg painBefore the procedure, in the immediate postoperative period (14 days) and in the late postoperative period (6 months).Pain change will be measured by a Visual Analogue Scale (VAS)
Intervention safetyThrough study completion, an average of 6 monthsAdverse events occurrence

Countries

Brazil

Contacts

Primary ContactRobert Meves, PhD
robertmeves@hotmail.com+55112176-1525
Backup ContactSybele Saska Specian, PhD
pesquisa@plenum.bio+551131099068

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026